Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01102244 | A Study to Evaluate the Clinical Efficacy and Safety of Tobradex® ST Compared to Azasite® in the Treatment of Subjects With Moderate to Severe Chronic Blepharitis | PHASE3 | COMPLETED | 122 | — | — | Apr 1, 2010 | - | Jun 11, 2012 | 1 | United States |
| Arm | Type | Description |
|---|---|---|
| Tobradex ST | EXPERIMENTAL | tobramycin 0.3%, dexamethasone 0.05% |
| Azasite | ACTIVE_COMPARATOR | azithromycin 1% |
| Name | Type | Description |
|---|---|---|
| Tobradex ST | DRUG | tobramycin / dexamethasone ophthalmic suspension 0.3%/0.05% 1 drop 4 times daily for 14 days |
| Azasite | DRUG | azithromycin 1% 1 drop twice daily for 2 days, then once daily for 12 days |
Inclusion Criteria: * Have diagnosis of moderate to severe chronic blepharitis defined by a minimum score of at least "1" for one of the lid signs, one of the conjunctival signs, and one of the symptoms in at least one eye * Have a minimum global score (the total signs and symptoms score) of 5 in t...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Glaukos Corp | GKOS | 1 | PHASE4 | GLK-321 low dose, GLK-321 mid dose |
| Tarsus Pharmaceuticals, Inc. | TARS | 1 | PHASE4 | Vehicle of TP-03 |